# Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease

> **NCT06945237** · NA · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 164 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Flupentixol-Melitracen + Lansoprazole
- **DRUG:** Lansoprazole and placebo

## Key facts

- **NCT ID:** NCT06945237
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-24
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-10-30
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06945237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06945237, "Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06945237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*